Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
0.270
+0.014 (5.47%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Mainz Biomed Revenue
Mainz Biomed had revenue of $260.39K in the quarter ending June 30, 2024, with 4.60% growth. This brings the company's revenue in the last twelve months to $917.20K, up 16.23% year-over-year. In the year 2023, Mainz Biomed had annual revenue of $895.48K with 69.00% growth.
Revenue (ttm)
$917.20K
Revenue Growth
+16.23%
P/S Ratio
5.89
Revenue / Employee
$12,918
Employees
71
Market Cap
6.91M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | 281.39K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMYNZ News
- 8 days ago - Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version - GlobeNewsWire
- 4 weeks ago - Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - GlobeNewsWire
- 5 weeks ago - Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - GlobeNewsWire
- 7 weeks ago - Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert - GlobeNewsWire
- 3 months ago - Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - GlobeNewsWire
- 4 months ago - Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test - GlobeNewsWire
- 4 months ago - Mainz Biomed Provides Half Year 2024 Corporate Update - GlobeNewsWire